SlideShare a Scribd company logo
1 of 48
Hardik Mistry
Date : 02/05/2014
Sterility
http://medicaldesign.com/site-files/medicaldesign.com/files/archive/medicaldesign.com/Whitepapers/SterilityTestin_00000021071.pdf
Pharmaceutical Sterility Testing Essential things to know, Steven Richter February 25, 2008
Source of Contamination in the cleanroom
External Internal
Introduction of contaminated outside
air or circulating air *
Staff
Staff Process
Impure process media or raw
materials
Production equipment, machines,
tools etc.
Inadequately cleaned materials, tools
etc.
Unsuitable building materials, work
materials
Mechanical abrasion in the cleanroom
Poor filter quality, not airtight filter seal surfaces, leakage in the ducting
system, abrasion in air recirculation equipment and in the ducting system
Cont….
Percentage Distribution of the Sources of Contamination
Process
20 - 30 %
People
30-40 %
Equipment
20 - 30 %
Process Media
5 - 10 %
Air
5 - 10 %
Investigation Area
M
M
M
M
M
INVESTIGATING STERILITY TEST FAILURES
(OOS)
Out Of Specification
• Test results that falls outside or does not comply with the pre-
determined acceptance criteria which have been established in
official compendia and/or company documentation
• (i.e. Filed application, Drug Master Files, Approved marketing
submissions, or Official compendia or Internal acceptance
criteria, Raw material specifications, In-process final product
testing etc.).
Laboratory Analysis
OOS (OOT) Result
Phase Ia Investigation
Phase Ib Investigation
Phase II Investigation
Phase III Investigation
Batch
Disposition
Satisfactory
Product Impact
Assessment
Manufacturing
Investigation
Phase Ia :
Preliminary Laboratory
investigation
No error
found
Initiate Phase Ib
Laboratory
Investigation
Obvious Error
No further
Investigation Required
Document and
Correct invalid Result
Definition
• Phase Ia investigation whether there has been a clear obvious errors
due to external circumstances as power failure or those that the analyst
has detected prior to generating data such as spilling sample that will
negate the requirement of Phase Ib investigation.
• For microbiological analysis this may be after analysis has been
completed and received during reading of the samples.
• It is expected that these issues are trended even if a laboratory
investigation Ib or II was not raised.
Phase Ia Investigation - Obvious Error
Obvious Errors
o Calculation error – Analyst and supervisor to review, both initial
and date correction
o Power outage – Analyst and supervisor document the event, “power
failure; analysis to be repeated on all associated analytical
documentation
o Equipment failure – Analyst and supervisor document the event,
annotate “Equipment failure’ analysis to be repeated“ Cross reference
the maintenance record.
Cont…
o Testing errors – For example, spilling of the sample, incomplete
transfer of sample, the analyst must document immediately.
For microbiology it could be growth on plate not in the test sample
area, negative or positive control failing
o Incorrect instrument parameters –
For example setting the detector at the wrong wavelength analyst and
supervisor document the event, annotate “incorrect instrument
parameter” analysis to be repeated on all associated analytical
documentation.
Phase Ib Investigation
Investigation by Analyst and
Supervisor
No assignable Cause
or
Evidence of Error Remains
Unclear
Contact –
Production/QA/Contract
Giver/QP
Phase II Investigation
Assignable Cause
(Root Cause Identified)
Test Data
Invalidated
Repeat
Analysis
Close Investigation
Generate CAPA
Record Results
Phase Ib Investigation - Definitions
Specification :
 Specifications are the critical quality standards and set of acceptance
criteria proposed and justified by the manufacturer and approved by the
regulatory authorities to which a drug substance, drug product or
materials at other stages of its manufacture should conform to be
considered acceptable for its intended use.
 Specification can be list of tests, references to analytical procedures and
appropriate acceptance criteria which are numerical limits, ranges or
other for the tests described.
Specifications are the condition of approval.
• Assignable cause – An identified reason for obtaining an OOS or
aberrant/anormalous result.
• No assignable cause – When no reason could be identified.
• Invalidated test – A test is considered invalid when the investigation
has determined the assignable cause.
• Reportable result – It is the final analytical result. This result is
appropriately defined in the written approved test method and derived
from one full execution of that method, starting from the original
sample.
• Warning level or trend execution : If two or more consecutive
samples exceed warning (alert) or if an increasing level of counts, or
same organisms identified, over a short period was identified
consideration should be given to treat results as action excursions.
Cont…
Hypothesis/Investigative Testing
It is the testing performed to help, confirm or discount a possible root
cause i.e what might have happened that can be tested.
for example it may include further testing regarding sample
filtration, sonication /extraction; and potential equipment failures etc.
Multiple hypothesis can be explored.
Investigation by Analyst and Supervisor
• Conducted using the laboratory investigation checklist.
• Contact production/contract giver/QP/MAH as appropriate.
• For microbiological OOS ensure all items related to the test failure are
retained such as other environmental plates, dilutions, ampoules/vials
of product, temperature data, auto pipettes, reagent- growth media.
• No implicated test environmental plates should be destroyed until the
investigation has been completed.
• The analyst and supervisor investigation should be restricted to
data/equipment/analysis review only.
• It may not be all-inclusive, but should be a good guideline to cover the
pertinent areas that need to be covered in any laboratory investigation.
• Correct test methodology and Correct sampling procedure followed eg.
Version number
• Correct sample(s) taken/tested (Check labels was it taken from correct
place)
• Sample integrity maintained, correct container and chain of custody
(was there an unusual event of problem)
• How were sample containers stored prior to use
Checklist
• Assessment of the possibility that the sample contamination has
occurred during the testing/re-testing procedure (eg. Sample left open
to air or unattended)
• Review equipment log books
• Appropriate standards and Controls used in the analysis which
performed as expected.
• System suitability conditions met (those before analysis and during
analysis)
• Correct and clean glassware used
• Correct pipette/ volumetric flasks volumes used
• Correct specification applied
Cont…
• Media/Reagents prepared according to procedure.
 Items were within expiry date
 A visual examination (solid and solution) reveals normal or
abnormal appearance
• The analyst is trained on the method.
• Interview analyst to assess knowledge of the correct procedure.
• Examination of the raw data, including chromatograms and spectra;
any anomalous or suspect peaks or data.
• Any previous issues with this assay
• Other potentially interfering testing/activities occurring at the time of
the test.
Cont…
• Any issues with environmental temperature/humidity within the area
whilst the test was conducted.
• Review of other data for other batches performed within the same
analysis set.
• Consideration of any other OOS results obtained on the batch of
material under test.
• Assessment of method validation.
Cont…
Additional consideration for microbiological analysis
• Are the isolates located as expected – on gloves, Finger dab marks, Contact
plates, filter membrane etc
• Was the sample media integral – i.e no cracks in plates
• Was there contamination present in other tests (or related tests) performed at the
same time, including environmental controls
• Were negative and positive controls satisfactory
• Were the correct media/reagents used
• Were the samples integral (Not leaking )
• Were the samples stored correctly (refrigerated)
• Were the samples held for the correct time before being tested.
• Were the media/reagents stored correctly before use
• Were the incubation conditions satisfactory
• Take photographs to document the sample at time of reading (include
plates, gram stains and any thing else that may be relevant)
Do not repeat the test unless it can be clearly shown that the test was
invalid for causes unrelated to the preparation under examination.
(a) Microbial growth is found in the negative controls.
(b) Data on microbial monitoring of the sterility testing facility show a
fault.
(c) A review on the testing procedure used for the test in the question
reveals a fault.
(d) After identifying the micro-organisms isolated from the containers
showing microbial growth may be ascribed without any doubt to faults
with respect to the materials and /or technique used in conducting the
test procedure.
Phase II
Conducting Failure Investigation
Follow Approved Protocol
Execute Investigation (Hypothesis Testing)
No Assignable Cause
OOS results Obtained
Confirm OOS
Assignable Cause
No further Retest
Report all Analysis
Batch
Disposition
Phase III Investigation
Report
Retest Results
Impact Assessment
Disposition Batch
Invalidate
original result
General
CAPA
Unknown Cause
No Assignable Cause
Hypothesis Testing
Re-Test
Re Sampling
Stability
Microbiology
Averaging
Outlier test
Phase II Investigation
• Conducted when phase I investigation did not reveal an assignable
laboratory error.
• Phase II are driven by written and approved instruction. Then started
manufacturing investigation to check whether there was a possible
manufacturing root cause..
• If not already notified the contract giver/MAH/QP should be notified
along with production and QA if a manufacturing site.
• Additional testing including the retest performed by the analyst other
than one performed the original test using the predefined retesting plan
and who should be experienced and qualified in the method.
• If the investigation determined analyst error all analysis using the same
techniques performed by the concerned analyst should be reviewed.
• Description of the testing should be written, and then approved by QA/Contract
giver/QA equivalent prior to initiating investigational testing and this testing
does not continue with the re measurement of the original preparation and may
not be used to replace the original result.
• Such description should include
 The hypothesis to the test the root cause being investigated
 What samples will be tested
 The exact execution of the testing
 How the data will be evaluated.
• If no assignable cause that could explain the results can be identified during the
manufacturing investigation or the assay failure investigation retesting may be
considered. Part of the investigation may involve retesting a portion of the
original sample.
Phase II Investigation – Unknown Cause/No Assignable Cause
• Performed on the original sample not a different sample which can be a 2nd
aliquot from the same sample that was the source of the original failure.
• In case of the insufficient quantity of the original sample remains to perform, for
further testing resample must be done with the approval of the QA/Contract
giver/ QA equivalent and whose records included in laboratory investigation.
• The decision to retest should be based on sound scientific judgement and the
test plan must be approved before re testing occurs which must include the
minimum number of the retests..
• Any statistical review with regards to % RSD and repeatability should relate the
values obtained during method validation (Accuracy, precision, and
intermediate precision) The number of retest should be statistically valid.
• Summarizes : Different sample – Approval of QA – Minimum Retest
Retesting
Microbiological Investigation
• The laboratory and manufacturing investigation need to be in depth
because the microbiological investigations are difficult to perform as the
result can be 1 to 2 weeks after the analysis was performed or may be
weeks after the batch was manufactured.
• It you do not determine the boundary of the suspect results it is difficult
to determine if it one or more batches impacted.
• The investigations should clearly state the hypothesis and who will be
responsible for the identified tasks.
• Source of the expected organism
• Review of the media
• Review of the Equipments/Utilities
• Environmental Monitoring trend
• Cleaning procedure review
• Disinfectant review
• All the possible root causes
• Review of decisions and actions taken in light of any new information
Microbiological Investigation check list
Due to the variability of microbiological results don’t limit the investigation to the
specific batch it should be broader to review historical results and trends
• Use scientific decisions/justifications and risk based analysis.
• Unusual events should be included to understand potential impacts.
• All potential sources of contamination need to be considered – process
flow the issue from sample storage to the test environment.
• Any identification may need to be at DNA/RAN level (bioburden
failures).
• Justification to perform repeat analysis (is sample left) retest or
resample if any.
Cont…
Stability – OOS
• Follow the investigation as above for phase I and Phase II.
• For Stability OOS situations regulatory agencies will require notification
within a short time point of discovery because the stability OOS should
link to the products Recall procedures.
• If abnormal results are found at any stability interval which predicts that
the test results may be OOS before the next testing interval, schedule
additional testing before the next scheduled testing interval. This will
help better determine appropriate actions to be taken.
• A case in which an OOT result suggests the potential or likelihood for
OOS results to occur before the expiration date within the same stability
study (or for other studies) on the same product is compliance alert.
OOT -OOS
• OOT is when a result is aberrant but within specification limits and
Historical data are needed to identify the OOT alerts.
• To facilitate the prompt identification of potential issues & to ensure
data quality, it is advantageous to use objective (often statistical)
methods that detect potential out-of-trend (OOT) stability data quickly.
• OOT alerts can be classified into three categorized to help identify the
appropriate depth for an investigation. It can be
− Analytical
− Process control and
− Compliance alerts
• As the alert level increases from analytical to process control to
compliance alert, the depth of investigation should increase.
Phase III Investigation
• If the batch is rejected, there still needs to be an investigation
 To Determine if other batches or products are affected
 Identification and implementation of corrective and preventive action
• The phase 3 investigation should review the completed manufacturing
investigation and combined laboratory investigation into the suspect
analytical results, and/or method validation for possible causes into the
results obtained.
• In the conclusion all of the results must be evaluated and investigation
report should contain a summary of the investigations performed and a
detailed conclusion.
• For microbiological investigations where appropriate use risk analysis
tools to support the decisions taken and conclusions drawn.
• It may not have been possible to determine the actual root cause
therefore a robust most probable root cause may have to be given.
• The batch quality must be determined and disposition decision taken.
• The decision to reject cannot be reversed as a result of further testing.
• The impact of OOS result on other batches, on going stability
studies, validated processes and testing procedures should be
determined by Quality control and Quality Assurance and be
documented in the conclusion along with appropriate corrective and
preventive actions.
Cont…
Batch Disposition
A. No Phase I or II obvious error
• If no laboratory or calculation errors are identified in the Phase I and
Phase II, there is no scientific basis for invalidating initial OOS results in
favor of passing retest results.
• All test results, both passing and suspect, should be reported (in all QC
documents and any Certificate of Analysis) and all data has to be
considered in batch release decisions.
B. Initial Sampling method inadequate
• If the investigation reveals that the initial sampling method was
inherently inadequate, a new sampling method must be developed
documented and reviewed and approved by the Quality Assurance
responsible for release.
• A consideration should be given to other lots samples by the same
method.
• An initial OOS result does not necessary mean the subject batch fails
and must be rejected.
• The OOS result should be investigated and the findings of the
investigation, including retest results, should be interpreted to evaluate
the batch and reach a decision regarding release or rejection which
should be fully documented.
Cont…
C. Where OOS result affect the batch quality
• In those cases where the investigation indicates an OOS result is caused
by a factor affecting the batch quality (i.e an OOS result is confirmed) the
result should be used in evaluating the quality of the batch.
• A confirmed OOS result indicates that the batches does not meet
established standards or specifications and should result in the batch’s
rejection and proper disposition.
• Other lots should be reviewed to assess impact.
D. For inconclusive investigations –
in case where an investigation does not reveal a cause for the OOS test
result and
does not confirm the OOS result
the OOS result should be given full consideration with the most
probable cause determined, in the batch or lot disposition decision by
the certifying QP and the potential for a batch specific variation also
needs considering.
• Any decision to release a batch, in spite of an initial OOS result that has
not been invalidated, should come only after a full investigation has
shown that the OOS result does not reflect the quality of the batch by
Quality Assurance/QP.
Sterility Failure Investigation
F sterility failure
F sterility failure
F sterility failure
F sterility failure
F sterility failure
F sterility failure
THANK YOU
Failure to analyze the failure is real failure.

More Related Content

What's hot

GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of AuditMegha bhise
 
Annual product reviews
Annual product reviewsAnnual product reviews
Annual product reviewsSyed Shakeeb
 
Vendor qualification
Vendor qualificationVendor qualification
Vendor qualificationDeekshitha HS
 
Vendor Audit
Vendor Audit Vendor Audit
Vendor Audit PRAVADA
 
Corrective and preventive action
Corrective  and preventive actionCorrective  and preventive action
Corrective and preventive actionSnehaGhadigaonkar
 
Deviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADeviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADr. Amsavel A
 
Auditing for Sterile Production Area
Auditing for Sterile Production AreaAuditing for Sterile Production Area
Auditing for Sterile Production AreaMANIKANDAN V
 
TSE/BSE Evaluation
TSE/BSE EvaluationTSE/BSE Evaluation
TSE/BSE EvaluationSridhar S
 
Special Provisions of Pharmaceutical Plant Layout
Special Provisions of Pharmaceutical Plant LayoutSpecial Provisions of Pharmaceutical Plant Layout
Special Provisions of Pharmaceutical Plant LayoutSaikat Bagchi
 
Water system validation by- Akshay kakde
Water system validation by- Akshay kakdeWater system validation by- Akshay kakde
Water system validation by- Akshay kakdeAkshay Kakde
 
CAPA Management | What is CAPA? | Corrective And Preventive Action
CAPA Management | What is CAPA? | Corrective And Preventive ActionCAPA Management | What is CAPA? | Corrective And Preventive Action
CAPA Management | What is CAPA? | Corrective And Preventive ActionAnil Chaudhari
 
Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]Kiran Kota
 
Auditing of quality assurance and maintenance of engineering department
Auditing of quality assurance and   maintenance of engineering departmentAuditing of quality assurance and   maintenance of engineering department
Auditing of quality assurance and maintenance of engineering departmentPriyanka Kandhare
 
Regulatory aspect of pharmaceutical change control system
Regulatory aspect of pharmaceutical  change control systemRegulatory aspect of pharmaceutical  change control system
Regulatory aspect of pharmaceutical change control systemDeveshDRA
 
Auditing of microbiology laboratory
Auditing of microbiology laboratoryAuditing of microbiology laboratory
Auditing of microbiology laboratoryNikita Amane
 

What's hot (20)

GMP compliances of Audit
GMP compliances of AuditGMP compliances of Audit
GMP compliances of Audit
 
Preparing and handling an inspection
Preparing and handling an inspectionPreparing and handling an inspection
Preparing and handling an inspection
 
Annual product reviews
Annual product reviewsAnnual product reviews
Annual product reviews
 
Water system validation
Water system validationWater system validation
Water system validation
 
Good Distribution Practices
Good Distribution PracticesGood Distribution Practices
Good Distribution Practices
 
Vendor qualification
Vendor qualificationVendor qualification
Vendor qualification
 
Vendor Audit
Vendor AuditVendor Audit
Vendor Audit
 
Vendor Audit
Vendor Audit Vendor Audit
Vendor Audit
 
Corrective and preventive action
Corrective  and preventive actionCorrective  and preventive action
Corrective and preventive action
 
Deviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPADeviation, OOS & complaint investigation and CAPA
Deviation, OOS & complaint investigation and CAPA
 
Auditing for Sterile Production Area
Auditing for Sterile Production AreaAuditing for Sterile Production Area
Auditing for Sterile Production Area
 
TSE/BSE Evaluation
TSE/BSE EvaluationTSE/BSE Evaluation
TSE/BSE Evaluation
 
Special Provisions of Pharmaceutical Plant Layout
Special Provisions of Pharmaceutical Plant LayoutSpecial Provisions of Pharmaceutical Plant Layout
Special Provisions of Pharmaceutical Plant Layout
 
Water system validation by- Akshay kakde
Water system validation by- Akshay kakdeWater system validation by- Akshay kakde
Water system validation by- Akshay kakde
 
CAPA Management | What is CAPA? | Corrective And Preventive Action
CAPA Management | What is CAPA? | Corrective And Preventive ActionCAPA Management | What is CAPA? | Corrective And Preventive Action
CAPA Management | What is CAPA? | Corrective And Preventive Action
 
Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]Handling of a fda inspection [compatibility mode]
Handling of a fda inspection [compatibility mode]
 
Auditing of quality assurance and maintenance of engineering department
Auditing of quality assurance and   maintenance of engineering departmentAuditing of quality assurance and   maintenance of engineering department
Auditing of quality assurance and maintenance of engineering department
 
Regulatory aspect of pharmaceutical change control system
Regulatory aspect of pharmaceutical  change control systemRegulatory aspect of pharmaceutical  change control system
Regulatory aspect of pharmaceutical change control system
 
Auditing of microbiology laboratory
Auditing of microbiology laboratoryAuditing of microbiology laboratory
Auditing of microbiology laboratory
 
Out of specifications
Out of specificationsOut of specifications
Out of specifications
 

Similar to F sterility failure

good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practicesrasika walunj
 
good laboratory practices
good laboratory practices good laboratory practices
good laboratory practices rasika walunj
 
Quality assurance
Quality assuranceQuality assurance
Quality assurancesanjay negi
 
Dr. negi quality assurance
Dr. negi quality assuranceDr. negi quality assurance
Dr. negi quality assurancesanjay negi
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxMohamed Fazil M
 
Good Laboratory Practices ppt
Good Laboratory Practices pptGood Laboratory Practices ppt
Good Laboratory Practices pptKrushna Yadav D K
 
good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practicesRajesh Raut
 
Good Laboratory Practice (GLP)
Good Laboratory Practice (GLP) Good Laboratory Practice (GLP)
Good Laboratory Practice (GLP) Rana Rana
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravanshravan dubey
 
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA Australia
 
Good Laboratory Practices Mubashir Maqbool
Good Laboratory Practices Mubashir MaqboolGood Laboratory Practices Mubashir Maqbool
Good Laboratory Practices Mubashir MaqboolMUBASHIR WANI
 
Pre analytic and postanalytic test management
Pre analytic and postanalytic test managementPre analytic and postanalytic test management
Pre analytic and postanalytic test managementVarsha Shahane
 
Clinical laboratory workflow - 9.pptx
Clinical laboratory workflow - 9.pptxClinical laboratory workflow - 9.pptx
Clinical laboratory workflow - 9.pptxMrI3rightside
 
Good laboratory practices awervness course ay
Good laboratory practices awervness course ayGood laboratory practices awervness course ay
Good laboratory practices awervness course ayAdel Younis
 

Similar to F sterility failure (20)

ISO 17025 – technical requirements
ISO 17025 – technical requirementsISO 17025 – technical requirements
ISO 17025 – technical requirements
 
good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practices
 
GLP
GLPGLP
GLP
 
good laboratory practices
good laboratory practices good laboratory practices
good laboratory practices
 
Quality assurance
Quality assuranceQuality assurance
Quality assurance
 
Dr. negi quality assurance
Dr. negi quality assuranceDr. negi quality assurance
Dr. negi quality assurance
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptx
 
Good Laboratory Practices ppt
Good Laboratory Practices pptGood Laboratory Practices ppt
Good Laboratory Practices ppt
 
Good laboratory practices
Good laboratory practicesGood laboratory practices
Good laboratory practices
 
good laboratory practices
good laboratory practicesgood laboratory practices
good laboratory practices
 
Out of Specification OOS.pptx
Out of Specification OOS.pptxOut of Specification OOS.pptx
Out of Specification OOS.pptx
 
Good Laboratory Practice (GLP)
Good Laboratory Practice (GLP) Good Laboratory Practice (GLP)
Good Laboratory Practice (GLP)
 
Out of specification shravan
Out of specification shravanOut of specification shravan
Out of specification shravan
 
Glp
GlpGlp
Glp
 
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...
TGA presentation: PICS Guide for GMP and Data Integrity relating to microbiol...
 
Good Laboratory Practices Mubashir Maqbool
Good Laboratory Practices Mubashir MaqboolGood Laboratory Practices Mubashir Maqbool
Good Laboratory Practices Mubashir Maqbool
 
Pre analytic and postanalytic test management
Pre analytic and postanalytic test managementPre analytic and postanalytic test management
Pre analytic and postanalytic test management
 
chem II 2019.ppt
chem II 2019.pptchem II 2019.ppt
chem II 2019.ppt
 
Clinical laboratory workflow - 9.pptx
Clinical laboratory workflow - 9.pptxClinical laboratory workflow - 9.pptx
Clinical laboratory workflow - 9.pptx
 
Good laboratory practices awervness course ay
Good laboratory practices awervness course ayGood laboratory practices awervness course ay
Good laboratory practices awervness course ay
 

More from Pharmaceutical

Pharmaceutical Qualification & Validation
Pharmaceutical Qualification & ValidationPharmaceutical Qualification & Validation
Pharmaceutical Qualification & ValidationPharmaceutical
 
Pharmaceutical Quality Risk Assessment
Pharmaceutical Quality Risk Assessment Pharmaceutical Quality Risk Assessment
Pharmaceutical Quality Risk Assessment Pharmaceutical
 
Pharmaceutical Good Manufacturing Practices
Pharmaceutical Good Manufacturing PracticesPharmaceutical Good Manufacturing Practices
Pharmaceutical Good Manufacturing PracticesPharmaceutical
 
Good Aseptic Practices ppt
Good Aseptic Practices  pptGood Aseptic Practices  ppt
Good Aseptic Practices pptPharmaceutical
 
DATA INTEGRITY GMP COMPLIANCE
DATA INTEGRITY GMP COMPLIANCEDATA INTEGRITY GMP COMPLIANCE
DATA INTEGRITY GMP COMPLIANCEPharmaceutical
 
New Approches towards the Anti-HIV chemotherapy
New Approches towards the Anti-HIV chemotherapyNew Approches towards the Anti-HIV chemotherapy
New Approches towards the Anti-HIV chemotherapyPharmaceutical
 
TOOLS OF CONTINUOUS IMPROVEMENT
TOOLS OF CONTINUOUS IMPROVEMENTTOOLS OF CONTINUOUS IMPROVEMENT
TOOLS OF CONTINUOUS IMPROVEMENTPharmaceutical
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practicePharmaceutical
 

More from Pharmaceutical (16)

Pharmaceutical Qualification & Validation
Pharmaceutical Qualification & ValidationPharmaceutical Qualification & Validation
Pharmaceutical Qualification & Validation
 
Pharmaceutical Quality Risk Assessment
Pharmaceutical Quality Risk Assessment Pharmaceutical Quality Risk Assessment
Pharmaceutical Quality Risk Assessment
 
Pharmaceutical Good Manufacturing Practices
Pharmaceutical Good Manufacturing PracticesPharmaceutical Good Manufacturing Practices
Pharmaceutical Good Manufacturing Practices
 
Good Aseptic Practices ppt
Good Aseptic Practices  pptGood Aseptic Practices  ppt
Good Aseptic Practices ppt
 
DATA INTEGRITY GMP COMPLIANCE
DATA INTEGRITY GMP COMPLIANCEDATA INTEGRITY GMP COMPLIANCE
DATA INTEGRITY GMP COMPLIANCE
 
ALKANES
ALKANESALKANES
ALKANES
 
New Approches towards the Anti-HIV chemotherapy
New Approches towards the Anti-HIV chemotherapyNew Approches towards the Anti-HIV chemotherapy
New Approches towards the Anti-HIV chemotherapy
 
Methane
MethaneMethane
Methane
 
Role Of Solvent
Role Of Solvent Role Of Solvent
Role Of Solvent
 
Molecular modelling
Molecular modelling Molecular modelling
Molecular modelling
 
QUALITY ASSURANCE
QUALITY ASSURANCEQUALITY ASSURANCE
QUALITY ASSURANCE
 
SAMPLING METHODS
SAMPLING METHODS SAMPLING METHODS
SAMPLING METHODS
 
PROCESS VALIDATION
PROCESS VALIDATIONPROCESS VALIDATION
PROCESS VALIDATION
 
TOOLS OF CONTINUOUS IMPROVEMENT
TOOLS OF CONTINUOUS IMPROVEMENTTOOLS OF CONTINUOUS IMPROVEMENT
TOOLS OF CONTINUOUS IMPROVEMENT
 
SOP
SOPSOP
SOP
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
 

Recently uploaded

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 

Recently uploaded (20)

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 

F sterility failure

  • 1. Hardik Mistry Date : 02/05/2014
  • 4. Source of Contamination in the cleanroom External Internal Introduction of contaminated outside air or circulating air * Staff Staff Process Impure process media or raw materials Production equipment, machines, tools etc. Inadequately cleaned materials, tools etc. Unsuitable building materials, work materials Mechanical abrasion in the cleanroom Poor filter quality, not airtight filter seal surfaces, leakage in the ducting system, abrasion in air recirculation equipment and in the ducting system
  • 5. Cont…. Percentage Distribution of the Sources of Contamination Process 20 - 30 % People 30-40 % Equipment 20 - 30 % Process Media 5 - 10 % Air 5 - 10 %
  • 8. Out Of Specification • Test results that falls outside or does not comply with the pre- determined acceptance criteria which have been established in official compendia and/or company documentation • (i.e. Filed application, Drug Master Files, Approved marketing submissions, or Official compendia or Internal acceptance criteria, Raw material specifications, In-process final product testing etc.).
  • 9. Laboratory Analysis OOS (OOT) Result Phase Ia Investigation Phase Ib Investigation Phase II Investigation Phase III Investigation Batch Disposition Satisfactory Product Impact Assessment Manufacturing Investigation
  • 10. Phase Ia : Preliminary Laboratory investigation No error found Initiate Phase Ib Laboratory Investigation Obvious Error No further Investigation Required Document and Correct invalid Result
  • 11. Definition • Phase Ia investigation whether there has been a clear obvious errors due to external circumstances as power failure or those that the analyst has detected prior to generating data such as spilling sample that will negate the requirement of Phase Ib investigation. • For microbiological analysis this may be after analysis has been completed and received during reading of the samples. • It is expected that these issues are trended even if a laboratory investigation Ib or II was not raised. Phase Ia Investigation - Obvious Error
  • 12. Obvious Errors o Calculation error – Analyst and supervisor to review, both initial and date correction o Power outage – Analyst and supervisor document the event, “power failure; analysis to be repeated on all associated analytical documentation o Equipment failure – Analyst and supervisor document the event, annotate “Equipment failure’ analysis to be repeated“ Cross reference the maintenance record.
  • 13. Cont… o Testing errors – For example, spilling of the sample, incomplete transfer of sample, the analyst must document immediately. For microbiology it could be growth on plate not in the test sample area, negative or positive control failing o Incorrect instrument parameters – For example setting the detector at the wrong wavelength analyst and supervisor document the event, annotate “incorrect instrument parameter” analysis to be repeated on all associated analytical documentation.
  • 14. Phase Ib Investigation Investigation by Analyst and Supervisor No assignable Cause or Evidence of Error Remains Unclear Contact – Production/QA/Contract Giver/QP Phase II Investigation Assignable Cause (Root Cause Identified) Test Data Invalidated Repeat Analysis Close Investigation Generate CAPA Record Results
  • 15. Phase Ib Investigation - Definitions Specification :  Specifications are the critical quality standards and set of acceptance criteria proposed and justified by the manufacturer and approved by the regulatory authorities to which a drug substance, drug product or materials at other stages of its manufacture should conform to be considered acceptable for its intended use.  Specification can be list of tests, references to analytical procedures and appropriate acceptance criteria which are numerical limits, ranges or other for the tests described. Specifications are the condition of approval.
  • 16. • Assignable cause – An identified reason for obtaining an OOS or aberrant/anormalous result. • No assignable cause – When no reason could be identified. • Invalidated test – A test is considered invalid when the investigation has determined the assignable cause. • Reportable result – It is the final analytical result. This result is appropriately defined in the written approved test method and derived from one full execution of that method, starting from the original sample. • Warning level or trend execution : If two or more consecutive samples exceed warning (alert) or if an increasing level of counts, or same organisms identified, over a short period was identified consideration should be given to treat results as action excursions. Cont…
  • 17. Hypothesis/Investigative Testing It is the testing performed to help, confirm or discount a possible root cause i.e what might have happened that can be tested. for example it may include further testing regarding sample filtration, sonication /extraction; and potential equipment failures etc. Multiple hypothesis can be explored.
  • 18. Investigation by Analyst and Supervisor • Conducted using the laboratory investigation checklist. • Contact production/contract giver/QP/MAH as appropriate. • For microbiological OOS ensure all items related to the test failure are retained such as other environmental plates, dilutions, ampoules/vials of product, temperature data, auto pipettes, reagent- growth media. • No implicated test environmental plates should be destroyed until the investigation has been completed. • The analyst and supervisor investigation should be restricted to data/equipment/analysis review only.
  • 19. • It may not be all-inclusive, but should be a good guideline to cover the pertinent areas that need to be covered in any laboratory investigation. • Correct test methodology and Correct sampling procedure followed eg. Version number • Correct sample(s) taken/tested (Check labels was it taken from correct place) • Sample integrity maintained, correct container and chain of custody (was there an unusual event of problem) • How were sample containers stored prior to use Checklist
  • 20. • Assessment of the possibility that the sample contamination has occurred during the testing/re-testing procedure (eg. Sample left open to air or unattended) • Review equipment log books • Appropriate standards and Controls used in the analysis which performed as expected. • System suitability conditions met (those before analysis and during analysis) • Correct and clean glassware used • Correct pipette/ volumetric flasks volumes used • Correct specification applied Cont…
  • 21. • Media/Reagents prepared according to procedure.  Items were within expiry date  A visual examination (solid and solution) reveals normal or abnormal appearance • The analyst is trained on the method. • Interview analyst to assess knowledge of the correct procedure. • Examination of the raw data, including chromatograms and spectra; any anomalous or suspect peaks or data. • Any previous issues with this assay • Other potentially interfering testing/activities occurring at the time of the test. Cont…
  • 22. • Any issues with environmental temperature/humidity within the area whilst the test was conducted. • Review of other data for other batches performed within the same analysis set. • Consideration of any other OOS results obtained on the batch of material under test. • Assessment of method validation. Cont…
  • 23. Additional consideration for microbiological analysis • Are the isolates located as expected – on gloves, Finger dab marks, Contact plates, filter membrane etc • Was the sample media integral – i.e no cracks in plates • Was there contamination present in other tests (or related tests) performed at the same time, including environmental controls • Were negative and positive controls satisfactory • Were the correct media/reagents used • Were the samples integral (Not leaking ) • Were the samples stored correctly (refrigerated) • Were the samples held for the correct time before being tested. • Were the media/reagents stored correctly before use • Were the incubation conditions satisfactory • Take photographs to document the sample at time of reading (include plates, gram stains and any thing else that may be relevant)
  • 24. Do not repeat the test unless it can be clearly shown that the test was invalid for causes unrelated to the preparation under examination. (a) Microbial growth is found in the negative controls. (b) Data on microbial monitoring of the sterility testing facility show a fault. (c) A review on the testing procedure used for the test in the question reveals a fault. (d) After identifying the micro-organisms isolated from the containers showing microbial growth may be ascribed without any doubt to faults with respect to the materials and /or technique used in conducting the test procedure.
  • 25. Phase II Conducting Failure Investigation Follow Approved Protocol Execute Investigation (Hypothesis Testing) No Assignable Cause OOS results Obtained Confirm OOS Assignable Cause No further Retest Report all Analysis Batch Disposition Phase III Investigation Report Retest Results Impact Assessment Disposition Batch Invalidate original result General CAPA
  • 26. Unknown Cause No Assignable Cause Hypothesis Testing Re-Test Re Sampling Stability Microbiology Averaging Outlier test
  • 27. Phase II Investigation • Conducted when phase I investigation did not reveal an assignable laboratory error. • Phase II are driven by written and approved instruction. Then started manufacturing investigation to check whether there was a possible manufacturing root cause.. • If not already notified the contract giver/MAH/QP should be notified along with production and QA if a manufacturing site. • Additional testing including the retest performed by the analyst other than one performed the original test using the predefined retesting plan and who should be experienced and qualified in the method. • If the investigation determined analyst error all analysis using the same techniques performed by the concerned analyst should be reviewed.
  • 28. • Description of the testing should be written, and then approved by QA/Contract giver/QA equivalent prior to initiating investigational testing and this testing does not continue with the re measurement of the original preparation and may not be used to replace the original result. • Such description should include  The hypothesis to the test the root cause being investigated  What samples will be tested  The exact execution of the testing  How the data will be evaluated. • If no assignable cause that could explain the results can be identified during the manufacturing investigation or the assay failure investigation retesting may be considered. Part of the investigation may involve retesting a portion of the original sample. Phase II Investigation – Unknown Cause/No Assignable Cause
  • 29. • Performed on the original sample not a different sample which can be a 2nd aliquot from the same sample that was the source of the original failure. • In case of the insufficient quantity of the original sample remains to perform, for further testing resample must be done with the approval of the QA/Contract giver/ QA equivalent and whose records included in laboratory investigation. • The decision to retest should be based on sound scientific judgement and the test plan must be approved before re testing occurs which must include the minimum number of the retests.. • Any statistical review with regards to % RSD and repeatability should relate the values obtained during method validation (Accuracy, precision, and intermediate precision) The number of retest should be statistically valid. • Summarizes : Different sample – Approval of QA – Minimum Retest Retesting
  • 30. Microbiological Investigation • The laboratory and manufacturing investigation need to be in depth because the microbiological investigations are difficult to perform as the result can be 1 to 2 weeks after the analysis was performed or may be weeks after the batch was manufactured. • It you do not determine the boundary of the suspect results it is difficult to determine if it one or more batches impacted. • The investigations should clearly state the hypothesis and who will be responsible for the identified tasks.
  • 31. • Source of the expected organism • Review of the media • Review of the Equipments/Utilities • Environmental Monitoring trend • Cleaning procedure review • Disinfectant review • All the possible root causes • Review of decisions and actions taken in light of any new information Microbiological Investigation check list Due to the variability of microbiological results don’t limit the investigation to the specific batch it should be broader to review historical results and trends
  • 32. • Use scientific decisions/justifications and risk based analysis. • Unusual events should be included to understand potential impacts. • All potential sources of contamination need to be considered – process flow the issue from sample storage to the test environment. • Any identification may need to be at DNA/RAN level (bioburden failures). • Justification to perform repeat analysis (is sample left) retest or resample if any. Cont…
  • 33. Stability – OOS • Follow the investigation as above for phase I and Phase II. • For Stability OOS situations regulatory agencies will require notification within a short time point of discovery because the stability OOS should link to the products Recall procedures. • If abnormal results are found at any stability interval which predicts that the test results may be OOS before the next testing interval, schedule additional testing before the next scheduled testing interval. This will help better determine appropriate actions to be taken. • A case in which an OOT result suggests the potential or likelihood for OOS results to occur before the expiration date within the same stability study (or for other studies) on the same product is compliance alert.
  • 34. OOT -OOS • OOT is when a result is aberrant but within specification limits and Historical data are needed to identify the OOT alerts. • To facilitate the prompt identification of potential issues & to ensure data quality, it is advantageous to use objective (often statistical) methods that detect potential out-of-trend (OOT) stability data quickly. • OOT alerts can be classified into three categorized to help identify the appropriate depth for an investigation. It can be − Analytical − Process control and − Compliance alerts • As the alert level increases from analytical to process control to compliance alert, the depth of investigation should increase.
  • 35. Phase III Investigation • If the batch is rejected, there still needs to be an investigation  To Determine if other batches or products are affected  Identification and implementation of corrective and preventive action • The phase 3 investigation should review the completed manufacturing investigation and combined laboratory investigation into the suspect analytical results, and/or method validation for possible causes into the results obtained. • In the conclusion all of the results must be evaluated and investigation report should contain a summary of the investigations performed and a detailed conclusion.
  • 36. • For microbiological investigations where appropriate use risk analysis tools to support the decisions taken and conclusions drawn. • It may not have been possible to determine the actual root cause therefore a robust most probable root cause may have to be given. • The batch quality must be determined and disposition decision taken. • The decision to reject cannot be reversed as a result of further testing. • The impact of OOS result on other batches, on going stability studies, validated processes and testing procedures should be determined by Quality control and Quality Assurance and be documented in the conclusion along with appropriate corrective and preventive actions. Cont…
  • 37. Batch Disposition A. No Phase I or II obvious error • If no laboratory or calculation errors are identified in the Phase I and Phase II, there is no scientific basis for invalidating initial OOS results in favor of passing retest results. • All test results, both passing and suspect, should be reported (in all QC documents and any Certificate of Analysis) and all data has to be considered in batch release decisions.
  • 38. B. Initial Sampling method inadequate • If the investigation reveals that the initial sampling method was inherently inadequate, a new sampling method must be developed documented and reviewed and approved by the Quality Assurance responsible for release. • A consideration should be given to other lots samples by the same method. • An initial OOS result does not necessary mean the subject batch fails and must be rejected. • The OOS result should be investigated and the findings of the investigation, including retest results, should be interpreted to evaluate the batch and reach a decision regarding release or rejection which should be fully documented.
  • 39. Cont… C. Where OOS result affect the batch quality • In those cases where the investigation indicates an OOS result is caused by a factor affecting the batch quality (i.e an OOS result is confirmed) the result should be used in evaluating the quality of the batch. • A confirmed OOS result indicates that the batches does not meet established standards or specifications and should result in the batch’s rejection and proper disposition. • Other lots should be reviewed to assess impact.
  • 40. D. For inconclusive investigations – in case where an investigation does not reveal a cause for the OOS test result and does not confirm the OOS result the OOS result should be given full consideration with the most probable cause determined, in the batch or lot disposition decision by the certifying QP and the potential for a batch specific variation also needs considering. • Any decision to release a batch, in spite of an initial OOS result that has not been invalidated, should come only after a full investigation has shown that the OOS result does not reflect the quality of the batch by Quality Assurance/QP.
  • 48. THANK YOU Failure to analyze the failure is real failure.